Chemical  ||| S:0 E:9 ||| NNP
derivatization  ||| S:9 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
neurosteroids  ||| S:27 E:41 ||| NN
for  ||| S:41 E:45 ||| IN
their  ||| S:45 E:51 ||| PRP$
trace  ||| S:51 E:57 ||| JJ
determination  ||| S:57 E:71 ||| NN
in  ||| S:71 E:74 ||| IN
sea  ||| S:74 E:78 ||| NN
lamprey  ||| S:78 E:86 ||| NN
by  ||| S:86 E:89 ||| IN
UPLC-MS ||| S:89 E:96 ||| NNP
/ ||| S:96 E:97 ||| NNP
MS  ||| S:97 E:100 ||| NNP
This  ||| S:100 E:105 ||| DT
article  ||| S:105 E:113 ||| NN
describes  ||| S:113 E:123 ||| VBZ
the  ||| S:123 E:127 ||| DT
development  ||| S:127 E:139 ||| NN
and  ||| S:139 E:143 ||| CC
validation  ||| S:143 E:154 ||| NN
of  ||| S:154 E:157 ||| IN
a  ||| S:157 E:159 ||| DT
sensitive  ||| S:159 E:169 ||| JJ
and  ||| S:169 E:173 ||| CC
robust  ||| S:173 E:180 ||| JJ
method  ||| S:180 E:187 ||| NN
for  ||| S:187 E:191 ||| IN
the  ||| S:191 E:195 ||| DT
determination  ||| S:195 E:209 ||| NN
of  ||| S:209 E:212 ||| IN
neurosteroids  ||| S:212 E:226 ||| NN
in  ||| S:226 E:229 ||| IN
sea  ||| S:229 E:233 ||| NN
lamprey ||| S:233 E:240 ||| NN
,  ||| S:240 E:242 ||| ,
an  ||| S:242 E:245 ||| DT
ancestral  ||| S:245 E:255 ||| JJ
animal  ||| S:255 E:262 ||| NN
in  ||| S:262 E:265 ||| IN
vertebrate  ||| S:265 E:276 ||| JJ
evolution ||| S:276 E:285 ||| NN
.  ||| S:285 E:287 ||| .
Chemical  ||| S:287 E:296 ||| NNP
derivatization  ||| S:296 E:311 ||| NN
was  ||| S:311 E:315 ||| VBD
used  ||| S:315 E:320 ||| VBN
to  ||| S:320 E:323 ||| TO
enhance  ||| S:323 E:331 ||| VB
the  ||| S:331 E:335 ||| DT
detection  ||| S:335 E:345 ||| NN
of  ||| S:345 E:348 ||| IN
neurosteroids  ||| S:348 E:362 ||| NNS
containing  ||| S:362 E:373 ||| VBG
ketone  ||| S:373 E:380 ||| JJ
function  ||| S:380 E:389 ||| NN
by  ||| S:389 E:392 ||| IN
ultra-high  ||| S:392 E:403 ||| JJ
performance  ||| S:403 E:415 ||| NN
liquid  ||| S:415 E:422 ||| FW
chromatography  ||| S:422 E:437 ||| FW
tandem  ||| S:437 E:444 ||| FW
mass  ||| S:444 E:449 ||| FW
spectrometry  ||| S:449 E:462 ||| FW
( ||| S:462 E:463 ||| -LRB-
UPLC-MS ||| S:463 E:470 ||| NNP
/ ||| S:470 E:471 ||| NNP
MS ||| S:471 E:473 ||| NNP
) ||| S:473 E:474 ||| -RRB-
.  ||| S:474 E:476 ||| .
Iminooxy  ||| S:476 E:485 ||| JJ
derivatives  ||| S:485 E:497 ||| NNS
of  ||| S:497 E:500 ||| IN
12  ||| S:500 E:503 ||| CD
oxosteroids  ||| S:503 E:515 ||| NNS
and  ||| S:515 E:519 ||| CC
three  ||| S:519 E:525 ||| CD
internal  ||| S:525 E:534 ||| JJ
standards  ||| S:534 E:544 ||| NNS
were  ||| S:544 E:549 ||| VBD
monitored  ||| S:549 E:559 ||| VBN
by  ||| S:559 E:562 ||| IN
positive  ||| S:562 E:571 ||| JJ
electrospray  ||| S:571 E:584 ||| JJ
tandem  ||| S:584 E:591 ||| JJ
mass  ||| S:591 E:596 ||| NN
spectrometry  ||| S:596 E:609 ||| VBZ
using  ||| S:609 E:615 ||| VBG
the  ||| S:615 E:619 ||| DT
neutral  ||| S:619 E:627 ||| JJ
loss  ||| S:627 E:632 ||| NN
of  ||| S:632 E:635 ||| IN
sulfate ||| S:635 E:642 ||| NN
.  ||| S:642 E:644 ||| .
Limit  ||| S:644 E:650 ||| NN
of  ||| S:650 E:653 ||| IN
quantification ||| S:653 E:667 ||| NN
,  ||| S:667 E:669 ||| ,
extraction  ||| S:669 E:680 ||| JJ
recovery  ||| S:680 E:689 ||| NN
and  ||| S:689 E:693 ||| CC
matrix  ||| S:693 E:700 ||| JJ
effect  ||| S:700 E:707 ||| NN
were  ||| S:707 E:712 ||| VBD
first  ||| S:712 E:718 ||| JJ
evaluated  ||| S:718 E:728 ||| NN
and  ||| S:728 E:732 ||| CC
SPE  ||| S:732 E:736 ||| NNP
using  ||| S:736 E:742 ||| VBG
C18  ||| S:742 E:746 ||| CD
sorbent  ||| S:746 E:754 ||| NNS
was  ||| S:754 E:758 ||| VBD
selected  ||| S:758 E:767 ||| VBN
after  ||| S:767 E:773 ||| IN
comparison  ||| S:773 E:784 ||| NN
with  ||| S:784 E:789 ||| IN
liquid ||| S:789 E:795 ||| JJ
/ ||| S:795 E:796 ||| CD
liquid  ||| S:796 E:803 ||| JJ
extraction  ||| S:803 E:814 ||| NN
and  ||| S:814 E:818 ||| CC
protein  ||| S:818 E:826 ||| NN
precipitation ||| S:826 E:839 ||| NN
.  ||| S:839 E:841 ||| .
Matrix  ||| S:841 E:848 ||| JJ
effect  ||| S:848 E:855 ||| NN
ranged  ||| S:855 E:862 ||| VBD
from  ||| S:862 E:867 ||| IN
89.6 ||| S:867 E:871 ||| CD
%  ||| S:871 E:873 ||| NN
to  ||| S:873 E:876 ||| TO
113.1 ||| S:876 E:881 ||| CD
%  ||| S:881 E:883 ||| NN
in  ||| S:883 E:886 ||| IN
plasma  ||| S:886 E:893 ||| NN
and  ||| S:893 E:897 ||| CC
from  ||| S:897 E:902 ||| IN
79.8 ||| S:902 E:906 ||| CD
%  ||| S:906 E:908 ||| NN
to  ||| S:908 E:911 ||| TO
100.0 ||| S:911 E:916 ||| CD
%  ||| S:916 E:918 ||| NN
in  ||| S:918 E:921 ||| IN
the  ||| S:921 E:925 ||| DT
brain ||| S:925 E:930 ||| NN
.  ||| S:930 E:932 ||| .
Recovery  ||| S:932 E:941 ||| NN
values  ||| S:941 E:948 ||| VBZ
ranged  ||| S:948 E:955 ||| VBN
from  ||| S:955 E:960 ||| IN
80.0 ||| S:960 E:964 ||| CD
%  ||| S:964 E:966 ||| NN
to  ||| S:966 E:969 ||| TO
103.8 ||| S:969 E:974 ||| CD
%  ||| S:974 E:976 ||| NN
in  ||| S:976 E:979 ||| IN
plasma  ||| S:979 E:986 ||| NN
and  ||| S:986 E:990 ||| CC
from  ||| S:990 E:995 ||| IN
86.3 ||| S:995 E:999 ||| CD
%  ||| S:999 E:1001 ||| NN
to  ||| S:1001 E:1004 ||| TO
107.9 ||| S:1004 E:1009 ||| CD
%  ||| S:1009 E:1011 ||| NN
in  ||| S:1011 E:1014 ||| IN
the  ||| S:1014 E:1018 ||| DT
brain ||| S:1018 E:1023 ||| NN
.  ||| S:1023 E:1025 ||| .
Chromatographic  ||| S:1025 E:1041 ||| JJ
separation  ||| S:1041 E:1052 ||| NN
was  ||| S:1052 E:1056 ||| VBD
achieved  ||| S:1056 E:1065 ||| VBN
by  ||| S:1065 E:1068 ||| IN
reverse  ||| S:1068 E:1076 ||| JJ
phase  ||| S:1076 E:1082 ||| NN
chromatography  ||| S:1082 E:1097 ||| NNS
( ||| S:1097 E:1098 ||| -LRB-
2.1mm×100mm ||| S:1098 E:1109 ||| NNP
,  ||| S:1109 E:1111 ||| ,
1.7µm  ||| S:1111 E:1117 ||| CD
particle  ||| S:1117 E:1126 ||| JJ
size ||| S:1126 E:1130 ||| NN
,  ||| S:1130 E:1132 ||| ,
C18 ||| S:1132 E:1135 ||| CD
)  ||| S:1135 E:1137 ||| -RRB-
with  ||| S:1137 E:1142 ||| IN
a  ||| S:1142 E:1144 ||| DT
binary  ||| S:1144 E:1151 ||| JJ
gradient  ||| S:1151 E:1160 ||| NN
between  ||| S:1160 E:1168 ||| IN
methanol  ||| S:1168 E:1177 ||| NN
and  ||| S:1177 E:1181 ||| CC
0.1 ||| S:1181 E:1184 ||| CD
%  ||| S:1184 E:1186 ||| NN
formic  ||| S:1186 E:1193 ||| NN
acid  ||| S:1193 E:1198 ||| NN
in  ||| S:1198 E:1201 ||| IN
water ||| S:1201 E:1206 ||| NN
.  ||| S:1206 E:1208 ||| .
Limit  ||| S:1208 E:1214 ||| NN
of  ||| S:1214 E:1217 ||| IN
quantification  ||| S:1217 E:1232 ||| NN
ranged  ||| S:1232 E:1239 ||| VBD
from  ||| S:1239 E:1244 ||| IN
5  ||| S:1244 E:1246 ||| CD
to  ||| S:1246 E:1249 ||| TO
10pg ||| S:1249 E:1253 ||| CD
/ ||| S:1253 E:1254 ||| CD
mL  ||| S:1254 E:1257 ||| JJ
and  ||| S:1257 E:1261 ||| CC
was  ||| S:1261 E:1265 ||| VBD
up  ||| S:1265 E:1268 ||| RP
to  ||| S:1268 E:1271 ||| TO
80  ||| S:1271 E:1274 ||| CD
times  ||| S:1274 E:1280 ||| NNS
lower  ||| S:1280 E:1286 ||| JJR
than  ||| S:1286 E:1291 ||| IN
those  ||| S:1291 E:1297 ||| DT
for  ||| S:1297 E:1301 ||| IN
non-derivatized  ||| S:1301 E:1317 ||| JJ
steroids ||| S:1317 E:1325 ||| NNS
.  ||| S:1325 E:1327 ||| .
Accuracy  ||| S:1327 E:1336 ||| NNP
and  ||| S:1336 E:1340 ||| CC
precision  ||| S:1340 E:1350 ||| NN
parameters  ||| S:1350 E:1361 ||| NNS
were  ||| S:1361 E:1366 ||| VBD
determined  ||| S:1366 E:1377 ||| VBN
and  ||| S:1377 E:1381 ||| CC
inter-  ||| S:1381 E:1388 ||| JJ
and  ||| S:1388 E:1392 ||| CC
intra-day  ||| S:1392 E:1402 ||| JJ
at  ||| S:1402 E:1405 ||| IN
three  ||| S:1405 E:1411 ||| CD
concentrations ||| S:1411 E:1425 ||| NNS
:  ||| S:1425 E:1427 ||| :
50 ||| S:1427 E:1429 ||| CD
,  ||| S:1429 E:1431 ||| ,
500  ||| S:1431 E:1435 ||| CD
and  ||| S:1435 E:1439 ||| CC
5000pg ||| S:1439 E:1445 ||| NNP
/ ||| S:1445 E:1446 ||| NNP
mL ||| S:1446 E:1448 ||| NNP
.  ||| S:1448 E:1450 ||| .
This  ||| S:1450 E:1455 ||| DT
method  ||| S:1455 E:1462 ||| NN
was  ||| S:1462 E:1466 ||| VBD
applied  ||| S:1466 E:1474 ||| VBN
to  ||| S:1474 E:1477 ||| TO
analyze  ||| S:1477 E:1485 ||| VB
real  ||| S:1485 E:1490 ||| JJ
samples.  ||| S:1490 E:1499 ||| CD
progesterone  ||| S:1499 E:1512 ||| NNS
( ||| S:1512 E:1513 ||| -LRB-
P ||| S:1513 E:1514 ||| NN
) ||| S:1514 E:1515 ||| -RRB-
,  ||| S:1515 E:1517 ||| ,
pregnenolone  ||| S:1517 E:1530 ||| NNS
( ||| S:1530 E:1531 ||| -LRB-
P5 ||| S:1531 E:1533 ||| NNP
) ||| S:1533 E:1534 ||| -RRB-
,  ||| S:1534 E:1536 ||| ,
7-hydroxy-pregnenolpne  ||| S:1536 E:1559 ||| NNP
( ||| S:1559 E:1560 ||| -LRB-
7P5 ||| S:1560 E:1563 ||| NNP
) ||| S:1563 E:1564 ||| -RRB-
,  ||| S:1564 E:1566 ||| ,
17-hydroxy-pregnenolpne  ||| S:1566 E:1590 ||| NNP
( ||| S:1590 E:1591 ||| -LRB-
17P5 ||| S:1591 E:1595 ||| NNP
) ||| S:1595 E:1596 ||| -RRB-
dehydroepiandrosterone  ||| S:1596 E:1619 ||| NNS
( ||| S:1619 E:1620 ||| -LRB-
DHEA ||| S:1620 E:1624 ||| NNP
) ||| S:1624 E:1625 ||| -RRB-
,  ||| S:1625 E:1627 ||| ,
androstenedienone  ||| S:1627 E:1645 ||| NNS
( ||| S:1645 E:1646 ||| -LRB-
A4 ||| S:1646 E:1648 ||| NNP
) ||| S:1648 E:1649 ||| -RRB-
,  ||| S:1649 E:1651 ||| ,
testosterone  ||| S:1651 E:1664 ||| NNS
( ||| S:1664 E:1665 ||| -LRB-
T ||| S:1665 E:1666 ||| NN
) ||| S:1666 E:1667 ||| -RRB-
,  ||| S:1667 E:1669 ||| ,
dihydrotestosterone  ||| S:1669 E:1689 ||| NNS
( ||| S:1689 E:1690 ||| -LRB-
DHT ||| S:1690 E:1693 ||| NNP
) ||| S:1693 E:1694 ||| -RRB-
,  ||| S:1694 E:1696 ||| ,
allopregnanolone  ||| S:1696 E:1713 ||| NNS
( ||| S:1713 E:1714 ||| -LRB-
THP ||| S:1714 E:1717 ||| NNP
) ||| S:1717 E:1718 ||| -RRB-
,  ||| S:1718 E:1720 ||| ,
11-hydroxy-androstenedienone  ||| S:1720 E:1749 ||| NNP
( ||| S:1749 E:1750 ||| -LRB-
11A4 ||| S:1750 E:1754 ||| NNP
)  ||| S:1754 E:1756 ||| -RRB-
and  ||| S:1756 E:1760 ||| CC
11-Deoxycortisol  ||| S:1760 E:1777 ||| NNP
( ||| S:1777 E:1778 ||| -LRB-
S ||| S:1778 E:1779 ||| NNP
)  ||| S:1779 E:1781 ||| -RRB-
were  ||| S:1781 E:1786 ||| VBD
measured  ||| S:1786 E:1795 ||| VBN
in  ||| S:1795 E:1798 ||| IN
sea  ||| S:1798 E:1802 ||| NN
lamprey  ||| S:1802 E:1810 ||| NN
brain  ||| S:1810 E:1816 ||| NN
and  ||| S:1816 E:1820 ||| CC
plasma  ||| S:1820 E:1827 ||| JJ
matrixes ||| S:1827 E:1835 ||| NN
.  ||| S:1835 E:1837 ||| .
